8-Foot-Up-and-Go Test is Associated with Hospitalizations and Mortality in Idiopathic Pulmonary Fibrosis: A Prospective Pilot Study
- 28 Downloads
To assess the prognostic value of the 8-foot-up-and-go test (8-FUGT) in pilot cohort of patients with idiopathic pulmonary fibrosis (IPF).
Thirty-four patients with IPF (68 ± 8 years) underwent 8-FUGT at baseline and were followed for up to 40 months. Receiver operating characteristics and age-adjusted Cox hazard ratios (HR) were analyzed for 8-FUGT, hospitalizations, and mortality. Correlation coefficients were determined between 8-FUGT and other exercise tests.
8-FUGT ≥ 6.9 s was found to be associated with hospitalization (sensitivity = 77%, specificity = 76%, p = 0.03) and mortality (sensitivity = 91%, specificity = 70% p = 0.008) in patients with IPF. Categorical models demonstrated that 8-FUGT ≥ 6.9 s was associated with 14.1- (p < 0.001) and 55.4-fold (p = 0.001) increased risks for hospitalization and mortality, respectively. In continuous models, for every 1-s slower performance in the 8-FUGT there were 54% [HR = 1.54, 95% CI (1.11–2.15) p = 0.01] increased risk for hospitalization and 94% [HR = 1.94, 95% CI (1.26–2.99) p = 0.003] increased risk for mortality. 8-FUGT was inversely related to 6-min walk distance (r = − 0.61), peak oxygen consumption (r = − 0.58), and peak work rate (r = − 0.72), all p < 0.001.
The 8-FUGT was strongly associated with hospitalizations and mortality in patients with IPF, as well as correlated with established prognostic markers. These novel findings suggest a prognostic value of the 8-FUGT for risk stratification, referral to pulmonary rehabilitation, and considering listing for lung transplantation. 8-FUGT is an inexpensive and practical tool that has prospective for implementation in clinical and research settings in IPF. Future prospective studies should evaluate the effect of changes in 8-FUGT on clinical outcomes.
KeywordsFunctional capacity Survival Prognostic predictors Risk stratification Clinical outcomes
BV was responsible for study design and conception, data collection, results interpretation, statistical analysis, drafting, writing, and submitting the manuscript. MRK supervising physician of the study was responsible for study design and conception, results interpretation, drafting the article, and revising it critically for important intellectual content. JM was involved in results interpretation, statistical analysis, drafting the article, and revising it critically for important intellectual content. AU and SI participated in results interpretation, statistical analysis, drafting the article, and revising it critically for important intellectual content. JO was involved in study design and conception, results interpretation, statistical analysis, drafting the article, and revising it critically for important intellectual content. All authors have read and approved the manuscript.
No funding was received for this study.
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 1.Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Muller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schunemann HJ (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183(6):788–824. https://doi.org/10.1164/rccm.2009-040GL CrossRefPubMedPubMedCentralGoogle Scholar
- 6.American Thoracic Society (ATS), and the European Respiratory Society (ERS) (2000) Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 161 (2 Pt 1):646–664Google Scholar
- 8.Mura M, Porretta MA, Bargagli E, Sergiacomi G, Zompatori M, Sverzellati N, Taglieri A, Mezzasalma F, Rottoli P, Saltini C, Rogliani P (2012) Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study. Eur Respir J 40(1):101–109. https://doi.org/10.1183/09031936.00106011 CrossRefPubMedGoogle Scholar
- 12.du Bois RM, Albera C, Bradford WZ, Costabel U, Leff JA, Noble PW, Sahn SA, Valeyre D, Weycker D, King TE Jr (2014) 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur Respir J 43(5):1421–1429. https://doi.org/10.1183/09031936.00131813 CrossRefPubMedGoogle Scholar
- 15.Tuppin MP, Paratz JD, Chang AT, Seale HE, Walsh JR, Kermeeen FD, McNeil KD, Hopkins PM (2008) Predictive utility of the 6-minute walk distance on survival in patients awaiting lung transplantation. J Heart Lung Transplant 27(7):729–734. https://doi.org/10.1016/j.healun.2008.03.017 CrossRefPubMedGoogle Scholar
- 17.Singh SJ, Puhan MA, Andrianopoulos V, Hernandes NA, Mitchell KE, Hill CJ, Lee AL, Camillo CA, Troosters T, Spruit MA, Carlin BW, Wanger J, Pepin V, Saey D, Pitta F, Kaminsky DA, McCormack MC, MacIntyre N, Culver BH, Sciurba FC, Revill SM, Delafosse V, Holland AE (2014) An official systematic review of the European Respiratory Society/American Thoracic Society: measurement properties of field walking tests in chronic respiratory disease. Eur Respir J 44(6):1447–1478. https://doi.org/10.1183/09031936.00150414 CrossRefPubMedGoogle Scholar
- 19.American College of Sports Medicine (2014) ACSM’s guidelines for exercise testing and prescription, 9th edn. Wolters Kluwer/Lippincott Williams & Wilkins Health, PhiladelphiaGoogle Scholar
- 20.Rikli RE, Jones CJ (2001) The senior fitness test manual. Human Kinetics, Champaign, pp. 111–151Google Scholar
- 27.Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, Gustafsson P, Hankinson J, Jensen R, McKay R, Miller MR, Navajas D, Pedersen OF, Pellegrino R, Wanger J (2005) Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 26(4):720–735. https://doi.org/10.1183/09031936.05.00034905 CrossRefPubMedGoogle Scholar
- 28.Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, Casaburi R, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson D, Macintyre N, McKay R, Miller MR, Navajas D, Pellegrino R, Viegi G (2005) Standardisation of the measurement of lung volumes. Eur Respir J 26(3):511–522. https://doi.org/10.1183/09031936.05.00035005 CrossRefPubMedGoogle Scholar
- 29.Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC (1993) Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 16:5–40CrossRefGoogle Scholar
- 30.ATS/ACCP statement on cardiopulmonary exercise testing. (2003) Am J Respir Crit Care Med 167 (2):211–277. https://doi.org/10.1164/rccm.167.2.211167/2/211
- 31.Fletcher GF, Ades PA, Kligfield P, Arena R, Balady GJ, Bittner VA, Coke LA, Fleg JL, Forman DE, Gerber TC, Gulati M, Madan K, Rhodes J, Thompson PD, Williams MA, American Heart Association Exercise CR, Prevention Committee of the Council on Clinical Cardiology CoNPA, Metabolism CoC, Stroke N, Council on E, Prevention (2013) Exercise standards for testing and training: a scientific statement from the American Heart Association. Circulation 128(8):873–934. https://doi.org/10.1161/CIR.0b013e31829b5b44 CrossRefPubMedGoogle Scholar
- 32.Fell CD, Liu LX, Motika C, Kazerooni EA, Gross BH, Travis WD, Colby TV, Murray S, Toews GB, Martinez FJ, Flaherty KR (2009) The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 179(5):402–407. https://doi.org/10.1164/rccm.200802-241OC CrossRefPubMedGoogle Scholar
- 33.Triantafillidou C, Manali E, Lyberopoulos P, Kolilekas L, Kagouridis K, Gyftopoulos S, Vougas K, Kotanidou A, Alchanatis M, Karakatsani A, Papiris SA (2013) The role of cardiopulmonary exercise test in IPF prognosis. Pulm Med 2013:514817. https://doi.org/10.1155/2013/514817 CrossRefPubMedPubMedCentralGoogle Scholar
- 38.Layton AM, Armstrong HF, Kim HP, Meza KS, D’Ovidio F, Arcasoy SM (2017) Cardiopulmonary exercise factors predict survival in patients with advanced interstitial lung disease referred for lung transplantation. Respir Med 126:59–67. https://doi.org/10.1016/j.rmed.2017.03.022 CrossRefPubMedGoogle Scholar